The TAT training course should teach the participants how to detect, quantify, safely handle and dispose alpha emitters in clinical settings. The participants will also learn how to synthesize selected radiopharmaceuticals labeled with alpha emitters.
Scope
The course consists of lectures and hands-on training sessions on safe handling of alpha emitters in clinical settings. It also includes the synthesis and quality control of radiopharmaceuticals labelled with alpha emitters, in particular Actinum-225 and Bismuth-213.
Course organisation
The course is delivered upon request in the frame of collaboration between JRC and partner hospitals in the field of targeted alpha therapy. The course typically lasts 1-2 days depending on training needs. The training sessions take place at the JRC Karlsruhe or in the hospitals involved.
Organisers
The course is organized by the JRC Karlsruhe, or in particular cases jointly with IAEA.
Learning outcomes
Upon completion of the course, students will be able to safely handle, detect and quantify alpha emitting radionuclides in clinical settings. They should also be able to synthesize alpha-emitter-labelled radiopharmaceuticals for clinical application.
Who can apply
Radiopharmacists, radiochemists, professionals and students in nuclear medicine.
Language of the course
English
Contact information
Alfred [dot] morgenstern
ec [dot] europa [dot] eu (Alfred[dot]morgenstern[at]ec[dot]europa[dot]eu)